199 related articles for article (PubMed ID: 26966379)
1. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Onco Targets Ther; 2016; 9():911-9. PubMed ID: 26966379
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Biomarkers; 2017 Mar; 22(2):157-164. PubMed ID: 27775427
[TBL] [Abstract][Full Text] [Related]
3. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Clin Lab; 2016 Sep; 62(9):1661-1669. PubMed ID: 28164586
[TBL] [Abstract][Full Text] [Related]
4. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
[TBL] [Abstract][Full Text] [Related]
5. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
6. Plasma Concentrations of Matrilysins MMP-7 and MMP-26 as Diagnostic Biomarkers in Breast Cancer.
Piskór BM; Przylipiak A; Dąbrowska E; Sidorkiewicz I; Niczyporuk M; Szmitkowski M; Ławicki S
J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33916127
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
Zajkowska M; Gacuta E; Kozłowska S; Lubowicka E; Głażewska EK; Chrostek L; Szmitkowski M; Pawłowski P; Zbucka-Krętowska M; Ławicki S
Adv Med Sci; 2019 Mar; 64(1):1-8. PubMed ID: 30227310
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer.
Zajkowska M; Lubowicka E; Malinowski P; Szmitkowski M; Ławicki S
Acta Biochim Pol; 2018 Dec; 65(4):621-628. PubMed ID: 30543720
[TBL] [Abstract][Full Text] [Related]
10. Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer.
Piskór BM; Przylipiak A; Dąbrowska E; Sidorkiewicz I; Niczyporuk M; Szmitkowski M; Ławicki S
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371324
[TBL] [Abstract][Full Text] [Related]
11. VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.
Ławicki S; Będkowska GE; Szmitkowski M
Growth Factors; 2013 Jun; 31(3):98-105. PubMed ID: 23688065
[TBL] [Abstract][Full Text] [Related]
12. Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?
Zajkowska M; Gacuta E; Lubowicka E; Szmitkowski M; Ławicki S
Acta Biochim Pol; 2020 Mar; 67(1):25-29. PubMed ID: 32160452
[TBL] [Abstract][Full Text] [Related]
13. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
14. Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients.
Lubowicka E; Przylipiak A; Zajkowska M; Piskór BM; Malinowski P; Fiedorowicz W; Ławicki S
Biomed Res Int; 2018; 2018():2124390. PubMed ID: 30151375
[TBL] [Abstract][Full Text] [Related]
15. Plasma Levels of Metalloproteinase 3 (MMP-3) and Metalloproteinase 7 (MMP-7) as New Candidates for Tumor Biomarkers in Diagnostic of Breast Cancer Patients.
Ławicki P; Malinowski P; Motyka J; Ławicki M; Kicman A; Kulesza M; Gacuta E; Guszczyn T; Januszkiewicz M; Zbucka-Krętowska M; Ławicki S
J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048701
[TBL] [Abstract][Full Text] [Related]
16. Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer.
Będkowska GE; Gacuta E; Zbucka-Krętowska M; Ławicki P; Szmitkowski M; Lemancewicz A; Motyka J; Kobus A; Chorąży M; Paniczko M; Ławicki S
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830735
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.
Będkowska GE; Gacuta E; Zajkowska M; Głażewska EK; Osada J; Szmitkowski M; Chrostek L; Dąbrowska M; Ławicki S
J Ovarian Res; 2017 Jun; 10(1):39. PubMed ID: 28662671
[TBL] [Abstract][Full Text] [Related]
18. [The plasma levels and diagnostic utility of matrix metalloproteinase-9 and CA 125 in cervical cancer patients].
Lubowicka E; Gacuta E; Zajkowska M; Głażewska EK; Przylipiak A; Chrostek L; Zbucka-Krętowska M; Ławicki S
Pol Merkur Lekarski; 2017 Jul; 43(253):10-14. PubMed ID: 28805195
[TBL] [Abstract][Full Text] [Related]
19. Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer.
Zajkowska M; Lubowicka E; Fiedorowicz W; Szmitkowski M; Jamiołkowski J; Ławicki S
Pathol Oncol Res; 2019 Oct; 25(4):1477-1486. PubMed ID: 30387014
[TBL] [Abstract][Full Text] [Related]
20. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
